Stockscreener 앱 받기
3.73
3.37%
-0.13
시간 외 거래:
3.80
0.07
+1.88%
Bluebird Bio Inc 주식(BLUE)의 최신 뉴스
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire
Gene Therapy Market Future Business Opportunities 2025-2032 | - openPR
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal - Dealbreaker
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs - BioSpace
bluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.com - Defense World
Stem Cell Therapy Market Growth | Trends, Size & Forecast - openPR
BMS to Acquire Abecma Partner 2seventy bio for $286M - Genetic Engineering & Biotechnology News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc.BLUE - PR Newswire
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal - Benzinga
Bristol Myers Squibb scoops up 2seventy bio for $286M - The Business Journals
Rhumbline Advisers Cuts Stock Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Bluebird bio’s chief medical officer Richard Colvin sells $2,288 in stock - Investing.com Australia
Bluebird bio’s chief commercial officer sells $1,959 in stock - Investing.com
Bluebird bio’s chief commercial officer sells $1,959 in stock By Investing.com - Investing.com Australia
bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - Defense World
bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio LawsuitBLUE - ACCESS Newswire
Levi & Korsinsky Reminds bluebird bio, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Lost Money on bluebird bio, Inc. (BLUE)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
Multiple Myeloma Treatment Market Size Report 2034 | - openPR
Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders - ACCESS Newswire
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
bluebird bio, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Turbulence at the FDA & bluebird Bio’s sale - STAT
bluebird bio stock slides for second day on buyout news - MSN
Shareholder Rights Advocates at Levi & Korsinsky Investigate bluebird bio, Inc. (BLUE) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Drug and Gene Delivery Devices Market Growth in Future Scope - openPR
Bluebird bio chief business officer Joseph Vittiglio sells $1,759 in stock - MSN
Levi & Korsinsky Reminds bluebird bio Investors of the Ongoing Investigation into Potential Violations of Securities LawsBLUE - ACCESS Newswire
BLUE DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire
Contrasting bluebird bio (NASDAQ:BLUE) and Valneva (NASDAQ:VALN) - Defense World
Carlyle and SK Capital’s Acquisition of bluebird bio - Global Legal Chronicle
bluebird bio (NASDAQ:BLUE) Given New $5.00 Price Target at Wells Fargo & Company - Defense World
Bluebird bio stock slides for second day on buyout news (NASDAQ:BLUE) - Seeking Alpha
JPMorgan Upgrades bluebird bio to Neutral From Underweight -February 24, 2025 at 07:36 am EST - Marketscreener.com
JP Morgan Upgrades bluebird bio (BLUE) - Nasdaq
Troubled gene therapy player bluebird sold for a song - pharmaphorum
Amneal pharma, Aramark, Bluebird Bio - TradingView
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital - BioSpace
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow - Genetic Engineering & Biotechnology News
bluebird bio announces take-private deal with Carlyle and SK Capital - MSN
IMMINENT BLUE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
bluebird bio plunges after take-private deal with Carlyle and SK Capital - MSN
Private equity firms rescue bluebird bio out of its misery - The Pharma Letter
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - MSN
Gene therapy maker bluebird to go private in discounted deal amid cash crunch - MSN
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity - MedCity News
Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com Nigeria
Bluebird bio stock plunges to 52-week low of $4.89 amid challenges - Investing.com Nigeria
Watkins Advises bluebird bio in Acquisition by Carlyle and SK Capital - Latham & Watkins LLP
Investment firms Carlyle and SK Capital to acquire gene therapy developer bluebird bio - BioProcess Insider
1.39%
0.55%
자본화:
|
볼륨(24시간):